Nonsurgical chemotherapy (verdinexor) treatment for canine brain tumors

Background and Purpose of the Trial

Every year, about three out of 100 dogs are diagnosed with brain tumors. A common type of those belong to the glioma family of brain tumors — which are the toughest to treat due to their ability to escape traditional treatment methods that destroy non-glioma tumors.

This study is testing a chemotherapy drug that may be better at destroying glioma tumors than others — without the need for brain surgery.

Study Design

Visit 1: Day 1

  • Neurologic examination
  • Blood draw for baseline bloodwork
  • Begin verdinexor (chemo) therapy twice per week

Visit 2: Day 7

  • Neurologic examination
  • Blood draw for a complete blood cell count and chemistry profile

Visit 3: Day 21

  • Neurologic examination
  • Blood draw for a complete blood cell count and chemistry profile

Visit 4: Day 42

  • Neurologic examination
  • Blood draw for a complete blood cell count and chemistry profile

Visit 5: Month 3

  • Neurologic examination
  • Blood draw for a complete blood cell count and chemistry profile

Visit 6: Month 6

  • Neurologic examination
  • Blood draw for a complete blood cell count and chemistry profile
  • Brain MRI to evaluate tumor’s response

Study Cost

The pet owner will only need to make a one-time payment of $700 at enrollment to cover the cost of chemotherapy. Examinations, bloodwork, and recheck MRIs are sponsored by the study.

condition(s)

glioma

eligibility information

To participate in this study:

  • Dogs must be over 10 kg (22 lbs) in body weight and have already had a brain tumor diagnosed on MRI
  • Dogs must be otherwise healthy with no other major diseases
  • Dogs cannot have previously received chemotherapy or radiation for this tumor

Enrollment Deadline

Enrollment ends December 31, 2030

contact information

If you are interested in enrolling in this clinical trial, please reach out to our team at [email protected] with your dog’s information as well as the contact information for his or her primary vet, and veterinary neurologist who performed the MRI.

Breonna Kusick
Clinical Trials Manager

(970) 305-0455

[email protected]